Olga Dakhova
Overview
Explore the profile of Olga Dakhova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
2726
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hegde M, Navai S, DeRenzo C, Joseph S, Sanber K, Wu M, et al.
Nat Cancer
. 2024 Apr;
5(6):880-894.
PMID: 38658775
In this prospective, interventional phase 1 study for individuals with advanced sarcoma, we infused autologous HER2-specific chimeric antigen receptor T cells (HER2 CAR T cells) after lymphodepletion with fludarabine (Flu)...
2.
Huang Y, Chen C, Sundaramurthy V, Slabicki M, Hao D, Watson C, et al.
Cancer Discov
. 2021 Aug;
12(1):220-235.
PMID: 34429321
Clonal hematopoiesis is a prevalent age-related condition associated with a greatly increased risk of hematologic disease; mutations in DNA methyltransferase 3A () are the most common driver of this state....
3.
Heczey A, Courtney A, Montalbano A, Robinson S, Liu K, Li M, et al.
Nat Med
. 2020 Oct;
26(11):1686-1690.
PMID: 33046868
Vα24-invariant natural killer T (NKT) cells have shown potent anti-tumor properties in murine tumor models and have been linked to favorable outcomes in patients with cancer. However, low numbers of...
4.
Hegde M, Joseph S, Pashankar F, DeRenzo C, Sanber K, Navai S, et al.
Nat Commun
. 2020 Jul;
11(1):3549.
PMID: 32669548
Refractory metastatic rhabdomyosarcoma is largely incurable. Here we analyze the response of a child with refractory bone marrow metastatic rhabdomyosarcoma to autologous HER2 CAR T cells. Three cycles of HER2...
5.
Lapteva N, Gilbert M, Diaconu I, Rollins L, Al-Sabbagh M, Naik S, et al.
Clin Cancer Res
. 2019 Sep;
25(24):7340-7350.
PMID: 31558475
Purpose: Current protocols for CD19 chimeric antigen receptor-expressing T cells (CD19.CAR-T cells) require recipients to tolerate preinfusion cytoreductive chemotherapy, and the presence of sufficient target antigen on normal or malignant...
6.
Ramos C, Rouce R, Robertson C, Reyna A, Narala N, Vyas G, et al.
Mol Ther
. 2018 Oct;
26(12):2727-2737.
PMID: 30309819
Second-generation (2G) chimeric antigen receptors (CARs) targeting CD19 are highly active against B cell malignancies, but it is unknown whether any of the costimulatory domains incorporated in the CAR have...
7.
Bollard C, Tripic T, Cruz C, Dotti G, Gottschalk S, Torrano V, et al.
J Clin Oncol
. 2018 Jan;
36(11):1128-1139.
PMID: 29315015
Purpose Transforming growth factor-β (TGF-β) production in the tumor microenvironment is a potent and ubiquitous tumor immune evasion mechanism that inhibits the expansion and function of tumor-directed responses; therefore, we...
8.
Nishimura C, Brenner D, Mukherjee M, Hirsch R, Ott L, Wu M, et al.
Blood
. 2017 Oct;
130(25):2739-2749.
PMID: 29079582
Adoptively transferred T-cell receptor (TCR)-engineered T cells depend on host-derived costimulation and cytokine signals for their full and sustained activation. However, in patients with cancer, both signals are frequently impaired....
9.
Gomes-Silva D, Mukherjee M, Srinivasan M, Krenciute G, Dakhova O, Zheng Y, et al.
Cell Rep
. 2017 Oct;
21(1):17-26.
PMID: 28978471
Antigen-independent tonic signaling by chimeric antigen receptors (CARs) can increase differentiation and exhaustion of T cells, limiting their potency. Incorporating 4-1BB costimulation in CARs may enable T cells to resist...
10.
Ramos C, Ballard B, Zhang H, Dakhova O, Gee A, Mei Z, et al.
J Clin Invest
. 2017 Aug;
127(9):3462-3471.
PMID: 28805662
Background: Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. However, adverse events, mainly mediated by the toxin component...